메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Hyung-seung Jin (University of Ulsan College of Medicine) 박윤 (한국과학기술연구원)
저널정보
대한생화학·분자생물학회 BMB Reports BMB Reports 제54권 제1호
발행연도
2021.1
수록면
2 - 11 (10page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Antibody-based therapeutics targeting the inhibitory receptorsPD-1, PD-L1, or CTLA-4 have shown remarkable clinical progresson several cancers. However, most patients do not benefitfrom these therapies. Thus, many efforts are being made toidentify new immune checkpoint receptor-ligand pathways thatare alternative targets for cancer immunotherapies. Nectin andnectin-like molecules are widely expressed on several types oftumor cells and play regulatory roles in T- and NK-cell functions. TIGIT, CD226, CD96 and CD112R on lymphoid cells are agroup of immunoglobulin superfamily receptors that interactwith Nectin and nectin-like molecules with different affinities. These receptors transmit activating or inhibitory signals uponbinding their cognate ligands to the immune cells. The integratedsignals formed by their complex interactions contribute to regulatingimmune-cell functions. Several clinical trials are currentlyevaluating the efficacy of anti-TIGIT and anti-CD112R blockadesfor treating patients with solid tumors. However, manyquestions still need to be answered in order to fully understandthe dynamics and functions of these receptor networks. Thisreview addresses the rationale behind targeting TIGIT, CD226,CD96, and CD112R to regulate T- and NK-cell functions anddiscusses their potential application in cancer immunotherapy.

목차

등록된 정보가 없습니다.

참고문헌 (9)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0